TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions.
“From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ...
MaRS Innovation to act as commercialization agent for York's life sciences and technology discoveries, leveraging new potential for York's existing $70 million in research initiatives
TORONTO, May 9, 2011 – York University has become the latest member of MaRS Innovation, the commercialization agent for many leading Toronto-based universities, hospitals and research institutes.
“York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a ...
Dr. John Rowlands’ X-ray Light Valve technology among the first TBRRI patents that MaRS Innovation will bring to market
January 26, 2011 (Thunder Bay, ON) – Today, MaRS Innovation welcomes Thunder Bay Regional Research Institute (TBRRI) as its newest member.
MaRS Innovation is an incorporated non-profit organization with an international, independent, industry-led Board of Directors. It is the commercialization agent for 16 member institutions that are leading Ontario life sciences and commercialization agents. Partners include the University of Toronto, Sunnybrook Health Sciences Centre, ...
TORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp..
The unique start-up company was spun-off from mobile health technologies developed Toronto's Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector.
MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto's ...
Toronto’s (U of T)
Funds secured from MaRS Innovation, HTX, OICR and CCR to speed commercialization of Xagenic's rapid molecular diagnostic technology
TORONTO (October 13, 2010) – MaRS Innovation today announced a $500,000 investment in its Toronto-based spin-off company, Xagenic Inc.
When combined with funds from other investors and lenders, the new working capital provided to Xagenic totals $1.04 million.
This follow‐on financing includes a $300,000 loan from HTX, The Health Technology Exchange; $200,000 from the Ontario Institute for Cancer Research; $40,000 from the Ontario Centre of Excellence ...
TORONTO (March 2, 2010) – MaRS Innovation is delighted to announce that two of its commercialization projects – notably an umbilical cord stem cell technology from Mount Sinai Hospital and nicotine addiction therapy from the Centre for Addiction and Mental Health (CAMH) - have received Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) funding.
This funding – each grant is valued at $150,000 – is third party validation of MaRS Innovation’s approach to commercializing its members’ discoveries. The CIHR performs rigorous due diligence and ...
TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some ...
TORONTO (June 29, 2009) – MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.
“With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Raphael (Rafi) Hofstein, President ...